- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare HDFC Pharma And Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.13 | 1.93 |
NAV | ₹15.36 | ₹35.80 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1568.02 Cr | ₹4917.81 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.13
1.93
NAV
₹15.36
₹35.80
Fund Started
14 Sep 2023
25 Jun 2018
Fund Size
₹1568.02 Cr
₹4917.81 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 22.58% | 18.67% |
3 Year | - | 22.76% |
5 Year | - | 26.66% |
1 Year
22.58%
18.67%
3 Year
-
22.76%
5 Year
-
26.66%
Holding Analysis
Equity | 99.10% | 98.79% |
Cash | 0.90% | 1.21% |
Equity
99.10%
98.79%
Cash
0.90%
1.21%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.29% |
Divi's Laboratories Ltd. | 8.50% |
Cipla Ltd. | 7.68% |
Lupin Ltd. | 5.35% |
Max Healthcare Institute Ltd. | 4.95% |
Krishna Institute of Medical Sciences Ltd | 4.01% |
Torrent Pharmaceuticals Ltd. | 3.83% |
Aster DM Healthcare Ltd. | 3.75% |
Ipca Laboratories Ltd. | 3.26% |
Glenmark Pharmaceuticals Ltd. | 3.18% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.56% |
Cipla Ltd. | 9.71% |
Dr. Reddy's Laboratories Ltd. | 8.28% |
Divi's Laboratories Ltd. | 6.05% |
Aurobindo Pharma Ltd. | 4.87% |
Lupin Ltd. | 4.47% |
Alkem Laboratories Ltd. | 3.87% |
Zydus Lifesciences Ltd. | 3.19% |
Gland Pharma Ltd. | 3.19% |
Mankind Pharma Ltd. | 2.81% |
Fund Manager
Name | Dhruv Muchhal | Dharmesh Kakkad |
Start Date | 14 Sep 2023 | 23 Feb 2021 |
Name
Dhruv Muchhal
Dharmesh Kakkad
Start Date
14 Sep 2023
23 Feb 2021
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
14 Sep 2023
25 Jun 2018
